IP Library › Granted Patent US 10,500,191
Granted Patent B2
US 10,500,191 · App. 15/743,203 · Granted Dec 10, 2019

Compositions and methods of use of antibacterial drug combinations

Inventors: Gautam Dantas (St. Louis, MO); Patrick Gonzales (St. Louis, MO); Kevin Forsberg (St. Louis, MO); Mitchell Pesesky (St. Louis, MO); Mayland Chang (St. Louis, MO); Shahriar Mobashery (St. Louis, MO)
Assignee: WASHINGTON UNIVERSITY
A61K31/407A61K31/424A61K31/43A61K31/431A61K31/496A61K31/546A61K45/06A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,500,191
App. No.
15/743,203
Granted
Dec 10, 2019
Kind
B2
Abstract

The present disclosure encompasses antibacterial compositions and methods of treating bacterial infections caused by resistant bacteria.

Claims (18)

1. A composition useful for the treatment of an infection caused by a methicillin-resistant Staphylococcus aureus (MRSA), wherein the resistance is due to a penicillin-binding protein 2a (PBP2a)-driven mechanism, the composition comprising:

i) at least one carbapenem or another β-lactam capable of binding the allosteric site of PBP2a;

ii) at least one β-lactamase inhibitor; and

iii) at least one β-lactam that binds the open configuration of the active site of PBP2a;

wherein the composition is selected from the group consisting of

a) meropenem/piperacillin/tazobactam (ME/PI/TZ);

b) cefepime/piperacillin/tazobactam (CP/PI/TZ);

c) aztreonam/piperacillin/tazobactam (AZ/PI/TZ);

d) meropenem/amoxicillin/tazobactam (ME/AX/TZ);

e) meropenem/amoxicillin/clavulanate (ME/AX/CV); and

f) imipenem/piperacillin/clavulanate (IM/PI/CV).

2. The composition of claim 1 , wherein the ratio of the carbapenem or another β-lactam to the β-lactamase inhibitor is in the range of 64:1 to 1:64.

3. The composition of claim 1 , wherein the ratio of the carbapenem or another β-lactam to the PBP2a binding β-lactam is in the range of 64:1 to 1:64.

4. The composition of claim 1 , wherein the ratio of the β-lactamase inhibitor to the PBP2a binding β-lactam is in the range of 64:1 to 1:64.

5. The composition of claim 1 , wherein the ratio of the antibiotics in the combination may range from 64:1:1, 1:64:1, and 1:1:64 to 1:1:1.

6. A pharmaceutical composition comprising a composition of claim 1 and at least one pharmaceutically acceptable excipient.

7. A method for treating an infection caused by a methicillin-resistant Staphylococcus aureus (MRSA) in a subject, wherein the resistance is due to a penicillin-binding protein 2a (PBP2a)-driven mechanism, the method comprising administering to the subject an effective amount of a composition of claim 1 .

8. A method for treating an infection caused by methicillin-resistant Staphylococcus aureus (MRSA), the method comprising administering to the subject an effective amount of a composition of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2022
From: CHANG, MAYLAND; MOBASHERY, SHAHRIAR
To: UNIVERSITY OF NOTRE DAME DU LAC
Reel/Frame 060853/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: DANTAS, GAUTAM; GONZALES, PATRICK; FORSBERG, KEVIN; PESESKY, MITCHELL
To: WASHINGTON UNIVERSITY
Reel/Frame 048942/0911 →
CONFIRMATORY LICENSE Recorded Jan 18, 2019
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048097/0580 →
Continuity (2)
Provisional Application 62190588 · Jul 9, 2015
Related Publication 20180200226A1 · Jul 19, 2018